Abnova (4133) reported revenue of NT$31.9 million for Oct 2026, +19.1% year on year and +30.8% from the previous month. Revenue for Jan–Oct 2026 was NT$285.6 million (-2.9% year on year).
In Oct 2026, it ranked No. 117 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$31.9 million | +19.1% | +30.8% |
| Sep 2026 | NT$24.4 million | -5.9% | -8.7% |
| Aug 2026 | NT$26.7 million | -14.7% | +1.6% |
| Jul 2026 | NT$26.3 million | -6.0% | -10.3% |
| Jun 2026 | NT$29.3 million | -6.4% | -1.8% |
| May 2026 | NT$29.9 million | +0.5% | +2.7% |
| Apr 2026 | NT$29.1 million | -4.6% | -15.4% |
| Mar 2026 | NT$34.4 million | -4.1% | +23.7% |
| Feb 2026 | NT$27.8 million | -12.4% | +8.2% |
| Jan 2026 | NT$25.7 million | +12.4% | -6.5% |
| Dec 2025 | NT$27.5 million | -3.0% | -7.3% |
| Nov 2025 | NT$29.6 million | -5.7% | +10.6% |
| Oct 2025 | NT$26.8 million | -5.2% | +3.3% |
| Sep 2025 | NT$26 million | -5.5% | -17.2% |
| Aug 2025 | NT$31.3 million | -5.3% | +11.9% |
| Jul 2025 | NT$28 million | -6.3% | -10.7% |
| Jun 2025 | NT$31.3 million | +12.2% | +5.4% |
| May 2025 | NT$29.7 million | -1.9% | -2.5% |
| Apr 2025 | NT$30.5 million | -9.0% | -15.0% |
| Mar 2025 | NT$35.9 million | +13.5% | +13.0% |
| Feb 2025 | NT$31.8 million | +20.7% | +38.9% |
| Jan 2025 | NT$22.9 million | -15.6% | -19.3% |
| Dec 2024 | NT$28.3 million | +5.8% | -9.8% |
| Nov 2024 | NT$31.4 million | -4.0% | +11.1% |
| Oct 2024 | NT$28.3 million | -18.0% | +3.0% |
Jan–Oct 2026 cumulative: NT$285.6 million (-2.9% YoY)
Other Biotech & Medical companies
Compare with peers: Abnova vs PEC / Abnova vs Lotus Pharm / Abnova vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16